Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 14, 2022 16:15 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., March 14, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
January 04, 2022 08:30 ET | Source: ARCA biopharma, Inc.

Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

Clinically important bradycardia is common in heart failure (HF) patients with persistent or paroxysmal atrial fibrillation (AF)In a Phase 2B clinical trial, the prevalence of clinically important...
December 02, 2021 08:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19

Topline readout of clinical trial results anticipated in first quarter of 2022 WESTMINSTER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company...
November 09, 2021 16:15 ET | Source: ARCA biopharma, Inc.

ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th

WESTMINSTER, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
November 02, 2021 16:15 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update

On-going Phase 2b clinical trial (ASPEN-COVID-19) evaluating rNAPc2 as a potential treatment for COVID-19DSMC interim analysis of safety and efficacy data from ASPEN-COVID-19 completed with...
October 28, 2021 16:30 ET | Source: ARCA biopharma, Inc.

ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data

Enrollment completion anticipated by year end 2021Topline data anticipated in first quarter of 2022 WESTMINSTER, Colo., Oct. 28, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a...
September 16, 2021 08:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19

First international patient enrolled in BrazilTrial approximately 75% enrolledrNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTopline trial data anticipated in...
August 16, 2021 08:05 ET | Source: ARCA biopharma, Inc.

ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th

WESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
August 09, 2021 08:00 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2

WESTMINSTER, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
August 04, 2021 16:15 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 expanded to South AmericaTopline data anticipated in the fourth quarter of 2021 WESTMINSTER, Colo., Aug. 04, 2021 ...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right